Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 20, 2021 08:00 ET | Source: G1 Therapeutics

G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
October 07, 2021 08:00 ET | Source: G1 Therapeutics

Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive the Drug Prior to Chemotherapy

RESEARCH TRIANGLE PARK, N.C., Oct. 07, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results from a retrospective analysis of...
October 01, 2021 16:30 ET | Source: G1 Therapeutics

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
October 01, 2021 07:45 ET | Source: G1 Therapeutics

G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services

RESEARCH TRIANGLE PARK, North Carolina, Oct. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the permanent J-code for...
September 15, 2021 06:45 ET | Source: G1 Therapeutics

G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force

RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will hire and train a 15-person...
September 03, 2021 07:45 ET | Source: G1 Therapeutics

G1 Therapeutics to Participate in Two Upcoming September Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two...
September 03, 2021 07:30 ET | Source: G1 Therapeutics

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
August 04, 2021 16:01 ET | Source: G1 Therapeutics

G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights

- Achieved $6.6 Million in Total Revenue, including $2.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Initiated Pivotal Phase 3 Trial in Metastatic Triple-Negative Breast Cancer...
August 04, 2021 08:00 ET | Source: G1 Therapeutics

G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Centers for Medicare &...
August 02, 2021 06:50 ET | Source: G1 Therapeutics

G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer

RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Andrew Perry as its...